

Correspondence

Isolated arterial calcifications of the lower extremities: A clue for *NT5E* mutation

Tjerk de Nijs^{a,1}, Juliette Albuissou^{b,1}, Charlotte W. Ockeloen^c, Anne Legrand^b, Xavier Jeunemaitre^b, Leo J. Schultze Kool^d, Niels P. Riksen^{a,*}

^a Dept. of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

^b University Paris Descartes, Paris Sorbonne Cité, AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, INSERM U970, PARC, Paris, France

^c Dept. of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

^d Dept. of Radiology, Radboud University Medical Center, Nijmegen, The Netherlands

ARTICLE INFO

Article history:

Received 5 February 2016

Accepted 16 March 2016

Available online 19 March 2016

Dear Editor

A forty-two year old man was referred to the Dept. of Vascular Medicine because of severe intermittent claudication of both legs, that started at the age of 27. He never smoked, used alcohol in moderation

and didn't use illicit drugs. His medication included acetylsalicylic acid and rosuvastatin. His family history was unremarkable, notably with no atherosclerotic disease and no consanguinity. His medical history revealed pain in several small joints of the hands, knees, and ankles since 1994, without rheumatological diagnosis.

Physical examination showed absent pulsations of the dorsal pedal arteries on both feet. Laboratory examination revealed normal serum concentration of total cholesterol (3.2 mmol/l), creatinine (71 μ mol/l), glucose (5.3 mmol/l), calcium (2.41 mmol/l), inorganic phosphate (0.99 mmol/l), parathyroid hormone (4.3 pmol/l), and 25-OH-vitamin D (56 μ mol/l).

A CT angiography of the thorax and abdomen was performed in 2007 revealing extensive arterial lower limb calcifications starting from the femoral artery (Fig. 1). Remarkably, the aorta and coronary




Fig. 1. Curved MPR (a) and transversal slide (b) of the upper leg demonstrating extensive calcifications in the wall of the superficial femoral artery.

* Corresponding author at: Dept. of Internal Medicine, Division of Vascular Medicine 463, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands.

E-mail address: niels.riksen@radboudumc.nl (N.P. Riksen).

¹ Shared first author.



Fig. 2. X-ray of the hands demonstrating small periarticular calcifications (see arrows).

circulation were free from calcifications. Conventional X-ray of his hands revealed extensive pericapsular calcifications of the small hand joints (Fig. 2).

Based on the combination of extensive isolated lower limb calcifications and small joint calcification, the patient was subsequently referred to the Dept. of Human Genetics and a genetic screening of the *NT5E* gene was proposed after informed consent.

Sanger sequencing of the 9 exons and exon–intron boundaries of the *NT5E* gene (NM_002526.3) was performed as described

elsewhere [1], and a novel homozygous splice-site variation of intron 3 was identified (c.751 + 2 T>C). This variation was predicted to abolish splicing by four bioinformatics tools (MAxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder). After skin biopsy and fibroblast culture, RNA was extracted and RT-PCR, gel electrophoresis and Sanger sequencing revealed total in-frame skipping of exon 3 (Fig. 3), with no minor transcripts, compared to control cDNA of an unaffected individual.

The clinical picture of arterial calcification of the lower extremities and joint calcifications has been described as early as 1914 and an inherited nature of this disease was suggested in 1954 (CALcification of Joints and Arteries; CALJA; #211800) [2]. In our patient, the typical distribution of the vascular calcifications in combination with the small joint calcification, suggested a recessive defect in the *NT5E* gene, as previously described in three families with CALJA [1]. *NT5E* encodes CD73, which is a membrane-bound ecto-5'-nucleotidase catalyzing the conversion of AMP to adenosine [3]. It is hypothesized that adenosine acts as a natural break on tissue calcification by inhibiting tissue-nonspecific alkaline phosphatase which degrades pyrophosphate, a potent tissue calcification inhibitor. Recently, the phenotype was extended to upper limb arterial calcifications, raising the question of phenotypic spectrum in CALJA [4]. Bisphosphonates, which are pyrophosphate analogs and potent inhibitors of tissue calcification, might prove beneficial in patients with *NT5E* mutations, which is currently under investigation (ClinicalTrials.gov Identifier: NCT01585402).

Conflict of interest

None.




Fig. 3. Gel electrophoresis (a) and Sanger electropherogram (b) of the *NT5E* cDNA exons 2 to 4 from the patient's fibroblast culture compared to an unaffected control. The 300 bp band (3a) corresponds to complete homozygous skipping of exon 3 (3b).



References

- [1] C. St Hilaire, S.G. Ziegler, T.C. Markello, A. Brusco, C. Groden, F. Gill, et al., *NT5E* mutations and arterial calcifications, *N. Engl. J. Med.* 364 (2011) 432–442.
- [2] J. Sharp, Heredo-familial vascular and articular calcification, *Ann. Rheum. Dis.* 13 (1954) 15–27.
- [3] N.T. Snider, P.J. Altshuler, S. Wan, T.H. Welling, J. Cavalcoli, M.B. Omary, Alternative splicing of human *NT5E* in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73), *Mol. Biol. Cell* 25 (2014) 4024–4033.
- [4] Z. Zhang, J.W. He, W.Z. Fu, C.Q. Zhang, Z.L. Zhang, Calcification of joints and arteries: second report with novel *NT5E* mutations and expansion of the phenotype, *J. Hum. Genet.* 60 (2015) 561–564.